Compare Eos Energy Enterprises Inc (EOSE) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eos Energy Enterprises Inc vs BIO-TECHNE Corp — how do they compare? Eos Energy Enterprises Inc trades at $3.98 (market cap $1.55B), while BIO-TECHNE Corp trades at $71.76 (market cap $11.14B). The key difference: BIO-TECHNE Corp is far larger — about 7.2× Eos Energy Enterprises Inc's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals.
| EOSE | TECH | |
|---|---|---|
Market Cap | $1.55B | $11.14B |
Sector | Energy | Health |
52-Week High | $19.19 | $71.48 |
52-Week Low | $4.29 | $43.31 |
Enterprise Value | $1.79B | $11.22B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $3.99, down 6.99% on the day, reflecting a challenging fundamental picture with significant losses. The company reported a net loss of $969.65M on $114.20M revenue for 2025, though recent Q1 2026 results showed a surprise EPS beat. Technical indicators are predominantly bearish, with moving averages signaling strong selling pressure, while the stock is consolidating near a key $4 support level. Recent news highlights accelerating commercial execution, including a major project selection for the Golden Dome initiative and preliminary Q2 2026 results pointing to record quarterly revenue and backlog.
The outlook presents a high-risk, high-reward scenario. Significant revenue acceleration and project backlog growth offer potential upside, supported by a consensus analyst price target of $9.00 (125% upside). However, deep negative margins, substantial cash burn, and a highly leveraged balance sheet with 91.87% debt-to-asset ratio pose severe financial risks. Investment success hinges on the company's ability to achieve manufacturing scale and path to profitability in the competitive energy storage market.
Bio-Techne (TECH) trades at $71.69, up 0.65% today, near the $73.00 acquisition offer from Merck KGaA announced June 25, 2026. The stock shows bullish technical signals with moving averages supporting upside, though RSI indicates potential overbought conditions. Fundamentally, revenue held at $1.22B in 2025, but net income fell to $73.40M with margin compression. Analysts are split 50/50 buy/hold with a $67.75 consensus target, below the current price, reflecting acquisition uncertainty.
The outlook hinges on the Merck deal closure at $73.00, offering a 1.8% premium from current levels. Risks include shareholder litigation challenging the transaction's fairness and regulatory approval delays. Without the deal, high P/E of 102.12 and declining profitability pose downside risks. The acquisition provides a near-term floor, but execution volatility remains a concern for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
